Design Therapeutics, Inc. (DSGN)
$
10.21
-0.36 (-3.53%)
Key metrics
Financial statements
Free cash flow per share
-0.9203
Market cap
581.6 Million
Price to sales ratio
0
Debt to equity
0.0087
Current ratio
18.7084
Income quality
0.7747
Average inventory
0
ROE
-0.3056
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company focused on developing therapies for genetic diseases linked to nucleotide repeat expansions. Its portfolio includes treatments for Friedreich Ataxia, a monogenic, autosomal recessive disorder that progressively impairs multiple organ systems reliant on mitochondrial function, ultimately causing neurological, cardiac, and metabolic complications. The company is also working on therapies for Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited progressive neuromuscular disease affecting the skeletal muscle, heart, brain, and other systems. Additionally, Design Therapeutics is advancing its GeneTAC product candidate portfolio to target a variety of other nucleotide repeat expansion-driven genetic conditions, including Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. In its recent financial report, the company revealed a net loss of -$49,588,000.00 indicating challenges in its operations. Despite these difficulties, the gross profit stands at -$596,000.00 highlighting the company's performance from core activities. The diluted earnings per share (EPS) is -$0.88 taking into account possible share dilution, while the revenue achieved was $0.00 signifying its focused efforts in a niche market. The company’s stock is identified by the symbol '$DSGN' in the financial market. On the market front, Design Therapeutics’ stock is priced affordably at $6.05 making it an attractive option for budget-conscious investors. The stock also exhibits a low average trading volume of 431,361.00 reflecting reduced activity in the market. With a market capitalization of $581,599,959.00 the company is categorized as a small-cap player, positioning it well within the industry. Being a key contributor to the Biotechnology industry, Design Therapeutics significantly influences the overall market landscape. Furthermore, it operates within the Healthcare sector, continuously driving innovation and growth amidst the evolving dynamics of the biopharmaceutical domain.
Is Design Therapeutics, Inc. (DSGN) a good investment?
Investing in Design Therapeutics, Inc. (DSGN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Design Therapeutics, Inc. (DSGN)'s stock forecast?
Analysts predict Design Therapeutics, Inc. stock to fluctuate between $2.60 (low) and $10.97 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Design Therapeutics, Inc.'s market capitalization?
As of 2026-01-30, Design Therapeutics, Inc.'s market cap is $581,599,959, based on 56,963,757 outstanding shares.
How does Design Therapeutics, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Design Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Design Therapeutics, Inc. (DSGN) stock?
To buy Design Therapeutics, Inc. (DSGN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DSGN. Place an order (Market, Limit, etc.).
What is the best time to invest in Design Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Design Therapeutics, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$0.88 | Growth: -26.05%.
Where can I find Design Therapeutics, Inc.'s investor relations reports?
Visit https://www.designtx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Design Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Design Therapeutics, Inc. stock?
All-time high: $26.30 (2022-08-15) | All-time low: $1.94 (2023-08-22).
What are the key trends affecting Design Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
6 days ago
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of "Moderate Buy" from the five analysts that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company.
defenseworld.net
a month ago
Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report)'s stock price traded down 4.5% during mid-day trading on Wednesday. The company traded as low as $9.43 and last traded at $9.3540. 246,384 shares were traded during trading, an increase of 22% from the average session volume of 201,241 shares. The stock had previously closed at
globenewswire.com
2 months ago
CARLSBAD, Calif., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in fireside chats at the following upcoming investor conferences:
247wallst.com
2 months ago
The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as robust as Wall Street had hoped.
globenewswire.com
3 months ago
Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 in Friedreich Ataxia (FA) and DT-168 in Fuchs Endothelial Corneal Dystrophy (FECD) Ongoing Cash and Securities of $206.0 Million as of Third Quarter 2025 Support Continued Pipeline Advancement CARLSBAD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress and updated milestones across its portfolio of GeneTAC® candidates in addition to reporting financial results for the third quarter of 2025.
globenewswire.com
5 months ago
CARLSBAD, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of industry veteran Justin Gover to its Board of Directors, effective immediately.
seekingalpha.com
5 months ago
Design Therapeutics, Inc. (NASDAQ:DSGN ) Cantor Global Healthcare Conference 2025 September 4, 2025 10:55 AM EDT Company Participants Pratik Shah - Co-Founder, President, CEO, Principal Financial Officer & Executive Chairperson Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Presentation Joshua Schimmer Biotech Equity Research Analyst All right. We're ready to get started.
globenewswire.com
6 months ago
Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from Non-Human Primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program
globenewswire.com
8 months ago
Initial Data from the Ongoing, Blinded Phase 1 Single-Ascending Dose Trial Has Demonstrated Favorable Safety and Pharmacokinetics IND Application Submitted to Expand RESTORE-FA Trial to U.S. Sites; Notice Received from FDA Placing Clinical Hold on IND Application to Open U.S. Sites CARLSBAD, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the first Friedreich ataxia (FA) patient has been dosed via intravenous (IV) infusion in its RESTORE-FA (Reactivating Expression Suppressed Through Overcoming Repeat Expansion for FA) open-label Phase 1/2 multiple-ascending dose (MAD) clinical trial of DT-216P2.
globenewswire.com
8 months ago
CARLSBAD, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will present during the 2025 Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 p.m.
See all news
